Dallas, Texas 11/06/2013 (Financialstrend) – In Tuesday’s trading, the opening price of Santarus, Inc. (NASDAQ:SNTS) shares was $24.34, which climbed to an intraday high of $24.54 and dipped to a close of $24.32. Approximately 1.49 million shares were traded on Tuesday while an average volume of 1.78 million shares were traded over a 30 day period. The 52-week low of Santarus, Inc. (NASDAQ:SNTS) shares is $8.47 and its 52-week high is $28.10. The company has a market capitalization of $1.61 billion.
About the company
Santarus, Inc. (NASDAQ:SNTS) was incorporated on 22 April 2002. It is a specialty bio-pharmaceutical company that focuses on the acquisition, development and commercialization of various products that address needs of patients who have been treated by physician-specialists. As of 31 December 2012, its marketed 7 approved products included Uceris, Zegerid, Glumetza, Cycloset, tablets and Fenoglide tablets. As of 31 December 2012, its investigational-drugs included Ruconest Rifamycin SV MMX & SAN-300.
Marketed & Approved Products
Uceris extended-release tablets are available in 9mg tablets. These are locally long- acting corticosteroid and are an oral tablet formulation. This uses the multi-matrix system. Uceris is used for induction of remission in those patients who suffer from active, mild- moderate ulcerative colitis. Zegerid capsules & powder that is used in oral suspension. It is available in 20 mg & 40 mg dosage-strengths and is an immediate-release formulation of proton-pump inhibitor.
Zegerid is used for short-term treatment of active-duodenal ulcer, short term treatment of active-benign gastric ulcer, the treatment of gastroesophageal-reflux disease, maintaining the healing of erosive-esophagitis & reducing risk of upper-gastrointestinal, bleeding in critically-ill patients. Glumetza is available in 500mg and 1000mg tablets. It is an extended-release, once-daily, formulation of metformin. It incorporates drug-delivery technology. Glumetza is the adjunct to diet & exercise to improve glycemic-control in adult-patients suffering from type 2 diabetes.